Rychon D. J. van Dasselaar

Statistics

Publications

Citations

H-Index

Active since

2023

Affiliations

LinXis Biopharmaceuticals (Netherlands)(Current)

University of Amsterdam

Amsterdam University Medical Centers

Rychon D. J. van Dasselaar is an author at LinXis Biopharmaceuticals (Netherlands) specializing in animal models of cholestasis, molecular pharmacology, and fibroblast growth factor 19 signaling in bile acid synthesis.

ORCID

Publications per year

2023–2024

Publications

Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β

Joey A. Muns, Erik van Schooten, Rychon D. J. van Dasselaar et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2024 · 11 citations · Full text

Pharmacy, Bioengineering, Pathology +17

Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice

Roni F. Kunst, Isabelle Bolt, Rychon D. J. van Dasselaar et al. · JHEP Reports · 2023 · 10 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–2 of 2